Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Investigation of TAS-119 Monotherapy
NCT02448589 · Taiho Oncology, Inc. · PHASE1 · terminated · last registry update 2024-09-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Taiho Oncology, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AURKA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-18Results posted on the registry: CASI pharmaceuticals, Inc., ENMD-2076 (NCT02234986)
- 2024-12-16Results posted on the registry: M.D. Anderson Cancer Center, Alisertib + Pembrolizumab (NCT04555837)
- 2024-10-18Results posted on the registry: Mayo Clinic, Alisertib + Fulvestrant (NCT02860000)
- 2024-10-09Results posted on the registry: US Oncology Research, Paclitaxel + Alisertib (NCT02187991)
- 2024-09-05Also stopped (terminated): Taiho Oncology, Inc., TAS-119 + Paclitaxel (NCT02134067)
- 2024-08-02Also stopped (terminated): Astex Pharmaceuticals, Inc., AT9283 (NCT00522990)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision